Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00798707 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 709
- Enrollment target
NCT00798707 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 709 participants.
The verdict
NCT00798707, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 709 participants
- Enrollment target
Study Summary
The primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of DVS SR (25 and 50 mg/day) in the treatment of adults with Major Depressive Disorder. The study will also assess changes in sexual function and general and functional quality of life outcomes.
Interventions
- DRUG placebo
- DRUG Desvenlafaxine Succinate Sustained-Release (DVS SR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 709 participants |
| Start Date | 2008-12 |
| Est. Completion | 2010-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00798707
The ClinicalTrials.gov registry entry for NCT00798707 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 709 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00798707 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00798707 about?
NCT00798707 is a clinical study titled "Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder". The primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of DVS SR (25 and 50 mg/day) in the treatment of adults with Major Depressive Disorder. The study will also assess changes in sexual function and general and functional quality of life outcomes.
What is the current status of trial NCT00798707?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 709 participants. The study started on 2008-12. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00798707?
The interventions under investigation include: placebo (DRUG), Desvenlafaxine Succinate Sustained-Release (DVS SR) (DRUG).
Who is sponsoring clinical trial NCT00798707?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.